Skip to main content

View full-text article in PMC

. 2014 May 1;17(5):558–570. doi: 10.1089/jmf.2013.2836

Table 11.

Changes in the Safety Outcome Variables of the Subjects

	Bofutsushosan (n=55)	Placebo (n=56)	P value^a
ALT at baseline, IU/L	22.36±16.86	22±17.16
Week 8 – baseline	−3.57±8.72	−1.88±8.89	.732
P value^b	.0113^*	0.1838
AST at baseline, IU/L	21.31±10.38	19.66±7.69
Week 8 – baseline	−2.14±5.94	−1.17±5.5	.573
P value^b	.0243^*	.1801
BUN at baseline, mg/dL	14.02±4.15	12.99±3.53
Week 8 – baseline	−0.09±3.43	0.05±3.18	.181
P value^b	.8688	.9223
Creatinine at baseline, mg/dL	0.69±0.13	0.67±0.1
Week 8 – baseline	0±0.08	−0.01±0.08	.305
P value^b	.7476	.49

^{^a}

Bofutsushosan vs. placebo (by independent t test).

^{^b}

Pre- vs. post-treatment within group (by paired t test).

^{^*}

P<.05.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urine nitrogen.